The resurgence of covalent drugs
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Covalent drugs have proved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This review surveys the prevalence and pharmacological advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Covalent inhibitors, also known as irreversible inhibitors, are a class of inhibitors that bind to amino acid residues of target proteins through covalent bonds formed by mildly reactive functional groups to confer additional affinity, compared to that of non-covalent inhibitors, which achieve binding and inhibition of target proteins through non-covalent interactions such as hydrogen bond and van”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [30]
In the citing paper
“Recent improvements in structural biology and chemical reactivity have enabled the design and development of potent and selective covalent PPI inhibitors.”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“Aided by recent advancements in structural biology and chemistry, covalent inhibitors have emerged as a potentially effective approach towards PPI inhibition [37, 38].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“In the 1970s, researchers reported that covalent drugs produce hepatotoxicity resulting from off-target effects via unselectively modifying non-target proteins with their highly reactive groups [37, 45].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
In the citing paper
“The initial binding step (K1) and the subsequent chemical reaction step (kinact) are two important factors determining the selectivity of covalent inhibitors (Fig. 7) [37].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“For example, approximately 50% of patients with non-small-cell lung carcinoma (NSCLC) who initially responded to reversible EGFR inhibitors relapsed owing to the emergence of tumour cells that express EGFR with mutations at T790M and/or L858R in the ATP binding sit”
BackgroundThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118 · cited 1×
“An irreversible mechanism of action also helps to mitigate against competition by high intracellular concentrations of AT”
BackgroundLigand efficiency: a useful metric for lead selection
Hopkins, A. L., Groom, C. R., & Alex, A. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03069-7 · Cited by 1,846
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
Targeting proteases: successes, failures and future prospects
Turk, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2092 · Cited by 1,363
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Navigating chemical space for biology and medicine
Lipinski, C., & Hopkins, A. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,002
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 952
Cited by
Items 101–200 of 1,001
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Zhan, X., Li, Q., Xu, G., Xiao, X., & Bai, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1109938 · Cited by 181
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
O'Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21385 · Cited by 180
Erratum: Mechanistic enzymology in drug discovery: a fresh perspective
Holdgate, G. A., Meek, T. D., & Grimley, R. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.257 · Cited by 180
Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation
Zhang, T., Hatcher, J. M., Teng, M., Gray, N. S., & Kostic, M. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.09.012 · Cited by 178
“Most notable examples of these are aspirin and penicillin, which target cyclooxygenases and bacterial DD-transpeptidase, respectively (Singh et al., 2011).”
BackgroundAngst, D., Gessier, F., Janser, P., Vulpetti, A., Wälchli, R., Beerli, C., Littlewood-Evans, A., Dawson, J., Nuesslein-Hildesheim, B., Wieczorek, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01916 · Cited by 172
Multiscale methods in drug design bridge chemical and biological complexity in the search for cures
Amaro, R. E., & Mulholland, A. J. (2018) · Nature Reviews Chemistry · doi:10.1038/s41570-018-0148 · Cited by 177
“There is renewed and growing interest in developing covalent binders and inhibitors (for enzymes and other targets), for increased affinity and e.g. altered pharmacokinetics 126 .”
BackgroundDevelopment of an in-vivo active reversible butyrylcholinesterase inhibitor
Košak, U., Brus, B., Knez, D., Šink, R., Žakelj, S., Trontelj, J., Pišlar, A., Šlenc, J., Gobec, M., Živin, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39495 · Cited by 163
A Fragment-Based Method to Discover Irreversible Covalent Inhibitors of Cysteine Proteases
Kathman, S. G., Xu, Z., & Statsyuk, A. V. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500345q · Cited by 170
Robinson, M. W., Overmeyer, J. H., Young, A. M., Erhardt, P. W., & Maltese, W. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201006x · Cited by 172
Keap Calm, and Carry on Covalently
Wilson, A. J., Kerns, J. K., Callahan, J. F., & Moody, C. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400224q · Cited by 171
Mukherjee, H., Debreczeni, J., Breed, J., Tentarelli, S., Aquila, B., Dowling, J. E., Whitty, A., & Grimster, N. P. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02028g · Cited by 167
Self-citationRedox regulation of protein kinases
Truong, T. H., & Carroll, K. S. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.790873 · Cited by 169
Drug discovery for a new generation of covalent drugs
Kalgutkar, A. S., & Dalvie, D. K. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.688744 · Cited by 166
Arylfluorosulfate‐Based Electrophiles for Covalent Protein Labeling: A New Addition to the Arsenal
Martín‐Gago, P., & Olsen, C. A. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201806037 · Cited by 164
Jöst, C., Nitsche, C., Scholz, T., Roux, L., & Klein, C. D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006918 · Cited by 162
Cee, V. J., Volak, L. P., Chen, Y., Bartberger, M. D., Tegley, C., Arvedson, T., McCarter, J., Tasker, A. S., & Fotsch, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01018 · Cited by 156
The Taxonomy of Covalent Inhibitors
Tuley, A., & Fast, W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00315 · Cited by 157
“Targeted Covalent Inhibitors, which target a poorly-conserved non-catalytic nucleophile),(12) but here we attempt to use only previously established categories as a framework to classify enzyme inhibitors that use covalent bond formation in their mechanisms (Figure 1).”
BackgroundThe Proline Cycle As a Potential Cancer Therapy Target
Tanner, J. J., Fendt, S.-M., & Becker, D. F. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00215 · Cited by 160
Cisar, J. S., Weber, O. D., Clapper, J. R., Blankman, J. L., Henry, C. L., Simon, G. M., Alexander, J. P., Jones, T. K., Ezekowitz, R. A. B., O’Neill, G. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00951 · Cited by 174
The long and short non-coding RNAs modulating EZH2 signaling in cancer
Mirzaei, S., Gholami, M. H., Hushmandi, K., Hashemi, F., Zabolian, A., Canadas, I., Zarrabi, A., Nabavi, N., Aref, A. R., Crea, F., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01235-1 · Cited by 161
“Therefore, there is no need of continuous exposure to EZH2 inhibitors [88].”
BackgroundTheory and Applications of Covalent Docking in Drug Discovery: Merits and Pitfalls
Kumalo, H., Bhakat, S., & Soliman, M. (2015) · Molecules · doi:10.3390/molecules20021984 · Cited by 158
“However, not all drugs bind non-covalently to the active site; there are other categories of drugs, namely the covalent drugs [14].”
BackgroundInfluentialThe influence of the 'organizational factor' on compound quality in drug discovery
Leeson, P. D., & St-Gallay, S. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3552 · Cited by 162
Somoza, J. R., Koditek, D., Villaseñor, A. G., Novikov, N. Y., Wong, M. H. L., Liclican, A. C., Xing, W., Lagpacan, L., Wang, R., Schultz, B. E., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.634683 · Cited by 170
Krenske, E. H., Petter, R. C., & Houk, K. N. (2016) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.6b02188 · Cited by 158
Self-citationInterfering peptides targeting protein–protein interactions: the next generation of drugs?
Bruzzoni‐Giovanelli, H., Alezra, V., Wolff, N., Dong, C., Tufféry, P., & Rebollo, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.10.016 · Cited by 169
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Joshi, J. J., Coffey, H., Corcoran, E., Tsai, J. J.-Y., Huang, C. L., Ichikawa, K., Prajapati, S., Hao, M., Bailey, S. L., Wu, J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1865 · Cited by 162
The role of reversible and irreversible covalent chemistry in targeted protein degradation
Kiely-Collins, H., Winter, G. E., & Bernardes, G. J. L. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.03.005 · Cited by 147
“, 2017), enhanced ability to outcompete endogenous ligand binding, sustained target engagement resulting in less frequent dosing, increased ability to target shallow binding sites previously considered ‘‘undruggable’’, and potential to evade resistance mutations that plague reversible inhibitors and result in disease…”
BackgroundInfluentialComparative Evaluation of Covalent Docking Tools
Scarpino, A., Ferenczy, G. G., & Keserű, G. M. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00228 · Cited by 153
A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action
Campaner, E., Rustighi, A., Zannini, A., Cristiani, A., Piazza, S., Ciani, Y., Kalid, O., Golan, G., Baloglu, E., Shacham, S., et al. (2017) · Nature Communications · doi:10.1038/ncomms15772 · Cited by 146
Caldwell, R. D., Qiu, H., Askew, B. C., Bender, A. T., Brugger, N., Camps, M., Dhanabal, M., Dutt, V., Eichhorn, T., Gardberg, A. S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00794 · Cited by 143
Vandermause, J., Xie, Y., Lim, J. S., Owen, C. J., & Kozinsky, B. (2022) · Nature Communications · doi:10.1038/s41467-022-32294-0 · Cited by 147
“Accurate modeling of chemical reactions is a central challenge in computational physics, chemistry, and biology, and is at the heart of computer-aided design of covalent drugs [1] and next-generation catalysts for CO2 reduction [2].”
Learning from our mistakes: The ‘unknown knowns’ in fragment screening
Davis, B. J., & Erlanson, D. A. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.028 · Cited by 146
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
Wang, Z., Yang, J., Kirk, C. J., Fang, Y., Alsina, M., Badros, A. Z., Papadopoulos, K. P., Wong, A., Woo, T. M., Bomba, D., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.047662 · Cited by 146
Tokunaga, K., Sato, M., Kuwata, K., Miura, C., Fuchida, H., Matsunaga, N., Koyanagi, S., Ohdo, S., Shindo, N., & Ojida, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c07490 · Cited by 159
AI-Aided Design of Novel Targeted Covalent Inhibitors against SARS-CoV-2
Tang, B., He, F., Liu, D., He, F., Wu, T., Fang, M., Niu, Z., Wu, Z., & Xu, D. (2022) · Biomolecules · doi:10.3390/biom12060746 · Cited by 144
Targeting biomolecules with reversible covalent chemistry
Bandyopadhyay, A., & Gao, J. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.08.011 · Cited by 143
Investigating the Proteome Reactivity and Selectivity of Aryl Halides
Shannon, D. A., Banerjee, R., Webster, E. R., Bak, D. W., Wang, C., & Weerapana, E. (2014) · Journal of the American Chemical Society · doi:10.1021/ja4116204 · Cited by 141
Fassunke, J., Müller, F., Keul, M., Michels, S. Y. F., Dammert, M. A., Schmitt, A., Plenker, D., Lategahn, J., Heydt, C., Brägelmann, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07078-0 · Cited by 150
Brighty, G. J., Botham, R. C., Li, S., Nelson, L. T., Mortenson, D. E., Li, G., Morisseau, C. H. P., Wang, H., Hammock, B. D., Sharpless, K. B., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0530-4 · Cited by 148
Identification of highly selective covalent inhibitors by phage display
Chen, S., Lovell, S., Lee, S., Fellner, M., Mace, P. D., & Bogyo, M. S. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0733-7 · Cited by 148
Zhong, H.-J., Lu, L., Leung, K.-H., Wong, C. C. L., Peng, C., Yan, S.-C., Ma, D.-L., Cai, Z., David Wang, H.-M., & Leung, C.-H. (2015) · Chemical Science · doi:10.1039/c5sc02321a · Cited by 138
Covalent inhibitors: an opportunity for rational target selectivity
Lagoutte, R., Patouret, R., & Winssinger, N. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.05.008 · Cited by 138
Choy, C. J., Ling, X., Geruntho, J. J., Beyer, S. K., Latoche, J. D., Langton-Webster, B. C., Anderson, C. J., & Berkman, C. E. (2017) · Theranostics · doi:10.7150/thno.18719 · Cited by 142
Selective and reversible modification of kinase cysteines with chlorofluoroacetamides
Shindo, N., Fuchida, H., Sato, M., Watari, K., Shibata, T., Kuwata, K., Miura, C., Okamoto, K., Hatsuyama, Y., Tokunaga, K., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0204-3 · Cited by 146
Arafet, K., Serrano-Aparicio, N., Lodola, A., Mulholland, A. J., González, F. V., Świderek, K., & Moliner, V. (2020) · Chemical Science · doi:10.1039/d0sc06195f · Cited by 144
Battling Btk mutants with noncovalent inhibitors that overcome Cys481 and Thr474 mutations
Johnson, A. R., Kohli, P. B., Katewa, A., Gogol, E., Belmont, L. D., Choy, R., Penuel, E., Burton, L., Eigenbrot, C., Yu, C., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00480 · Cited by 137
A modular master regulator landscape controls cancer transcriptional identity
Paull, E. O., Aytes, A., Jones, S. J., Subramaniam, P. S., Giorgi, F. M., Douglass, E. F., Tagore, S., Chu, B., Vasciaveo, A., Zheng, S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.045 · Cited by 135
Larraufie, M.-H., Yang, W. S., Jiang, E., Thomas, A. G., Slusher, B. S., & Stockwell, B. R. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.018 · Cited by 136
Fragment-based covalent ligand discovery
Lu, W., Kostic, M., Zhang, T., Che, J., Patricelli, M. P., Jones, L. H., Chouchani, E. T., & Gray, N. S. (2021) · RSC Chemical Biology · doi:10.1039/d0cb00222d · Cited by 136
Inhibitor Mediated Protein Degradation
Long, M. J. C., Gollapalli, D. R., & Hedstrom, L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.04.008 · Cited by 133
Ouyang, X., Zhou, S., Su, C. T. T., Ge, Z., Li, R., & Kwoh, C. K. (2013) · Journal of Computational Chemistry · doi:10.1002/jcc.23136 · Cited by 134
Chang, J. W., Cognetta, A. B., Niphakis, M. J., & Cravatt, B. F. (2013) · ACS Chemical Biology · doi:10.1021/cb400261h · Cited by 134
Tsou, L. K., Lara-Tejero, M., RoseFigura, J. M., Zhang, Z. J., Wang, Y., Yount, J. S., Lefebre, M. D., Dossa, P. D., Kato, J., Guan, F., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b11575 · Cited by 133
Hatcher, J. M., Wu, G., Zeng, C., Zhu, J., Meng, F., Patel, S., Wang, W., Ficarro, S. B., Leggett, A. L., Powell, C. E., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.01.013 · Cited by 131
“Rationally designed covalent kinase inhibitors have recently experienced a resurgence of interest (Singh et al., 2011), and some have been approved by the FDA, including osimertinib and Ibrutinib for targeting mutant EGFR and BTK, respectively.”
BackgroundA road map for prioritizing warheads for cysteine targeting covalent inhibitors
Ábrányi‐Balogh, P., Petri, L., Imre, T., Szijj, P. A., Scarpino, A., Hrast, M., Mitrović, A., Fonović, U. P., Németh, K., Barreteau, H., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.010 · Cited by 140
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
Zhao, Z., Liu, Q., Bliven, S., Xie, L., & Bourne, P. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01815 · Cited by 126
Wang, Y.-R., Chen, S.-F., Wu, C.-C., Liao, Y.-W., Lin, T.-S., Liu, K.-T., Chen, Y.-S., Li, T., Chien, T., & Chan, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx742 · Cited by 129
Characterising covalent warhead reactivity
Martin, J. S., MacKenzie, C. J., Fletcher, D., & Gilbert, I. H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.04.002 · Cited by 125
“The nitriles (5, 7, 8) appear to react similarly with both cysteine and serine, but have relatively slow rates.”
Background10 Years Into the Resurgence of Covalent Drugs
De Vita, E. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 122
“Both these now familiar expressions were minted in pivotal reviews to which the reader is directed for an amplified discussion [6,12].”
BackgroundInfluentialBach, K., Beerkens, B. L. H., Zanon, P. R. A., & Hacker, S. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01268 · Cited by 125
Ainsliadimer A selectively inhibits IKKα/β by covalently binding a conserved cysteine
Dong, T., Li, C., Wang, X., Dian, L., Zhang, X., Li, L., Chen, S., Cao, R., Li, L., Huang, N., et al. (2015) · Nature Communications · doi:10.1038/ncomms7522 · Cited by 135
Diverse Redoxome Reactivity Profiles of Carbon Nucleophiles
Gupta, V., Yang, J., Liebler, D. C., & Carroll, K. S. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b01791 · Cited by 126
Bai, B., Belovodskiy, A., Hena, M. A., Kandadai, A. S., Joyce, M., Saffran, H. A., Shields, J. A., Khan, M. B., Arutyunova, E. I., Lu, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00616 · Cited by 127
Homer, J. A., Xu, L. Y., Namitharan, K., Zheng, Q., Choi, E. J., Kim, B. M., Sharpless, K. B., Zuilhof, H. T., Dong, J., & Moses, J. E. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00241-y · Cited by 139
Ligand–receptor interaction platforms and their applications for drug discovery
Fang, Y. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.715631 · Cited by 124
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Yang, J., Wang, Z., Fang, Y., Jiang, J., Zhao, F., Wong, H. L., Bennett, M. K., Molineaux, C. J., & Kirk, C. J. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.039164 · Cited by 133
Dalton, S. E., Dittus, L., Thomas, D. A., Convery, M. A., Nunes, J., Bush, J. T., Evans, J. P., Werner, T., Bantscheff, M., Murphy, J. A., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08979 · Cited by 119
Peterson, L. F., Sun, H., Liu, Y., Potu, H., Kandarpa, M., Ermann, M., Courtney, S. M., Young, M., Showalter, H. D., Sun, D., et al. (2015) · Blood · doi:10.1182/blood-2014-10-605584 · Cited by 124
Gupta, V., & Carroll, K. S. (2015) · Chemical Science · doi:10.1039/c5sc02569a · Cited by 132
Antony, M. L., Lee, J., Hahm, E., Kim, S., Marcus, A. I., Kumari, V., Ji, X., Yang, Z., Vowell, C. L., Wipf, P., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.496844 · Cited by 129
Mons, E., Roet, S., Kim, R. Q., & Mulder, M. P. C. (2022) · Current Protocols · doi:10.1002/cpz1.419 · Cited by 138
“…kinact/KI is generally accepted as a more suitable measure of two-step irreversible inhibitor potency (Holdgate et al., 2017; Schwartz et al., 2014; Singh et al., 2011; Strelow, 2017), in an analogous fashion to kcat/KM reflecting the efficiency of enzymatic substrate conversion (detailed…”
BackgroundHER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Pan, L., Li, J., Xu, Q., Gao, Z., Yang, M., Wu, X., & Li, X. (2024) · Medicine · doi:10.1097/md.0000000000038508 · Cited by 172
“…o r s b y c o v a l e n t b i nd i ng t o c y s t e i n e s i d e c h a i n s i n t h e A T P - b i nd i ng p o u c h o f t h e r e c e p t o r s [ 139 , 140 ] C li n i c a l a pp r o v a l f o r e x t e nd e d a d j u v a n t t h e r a p y f o ll o w i ng t r a s t u z u m a b a d j u v a n t t…”
Mons, E., Jansen, I. D. C., Loboda, J., van Doodewaerd, B. R., Hermans, J., Verdoes, M., van Boeckel, C. A. A., van Veelen, P. A., Turk, B., Turk, D., et al. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.8b11027 · Cited by 112
“SI-66 Appendix; Background on kinetic evaluation of (ir)reversible slow-binding inhibitors Conventional IC50 measurements are of limited value for characterizing potency of irreversible inhibitors, because a different value will be found when incubation time is longer or shorter.(34) The covalent inhibitors described…”
Covalent‐Allosteric Kinase Inhibitors
Weisner, J., Gontla, R., van der Westhuizen, L., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201502142 · Cited by 114
Palladium‐Catalyzed Fluorosulfonylvinylation of Organic Iodides
Zha, G., Zheng, Q., Leng, J., Wu, P., Qin, H., & Sharpless, K. B. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701162 · Cited by 120
Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
Flynn, J. M., Samant, N., Schneider-Nachum, G., Barkan, D. T., Yilmaz, N. K., Schiffer, C. A., Moquin, S. A., Dovala, D., & Bolon, D. N. (2022) · eLife · doi:10.7554/elife.77433 · Cited by 117
“site enables the design of covalent inhibitors that provide advantages such as increased potency, selectivity, and duration of inhibition (Singh et al., 2011).”
BackgroundNitriles: an attractive approach to the development of covalent inhibitors
Bonatto, V., Lameiro, R. F., Rocho, F. D. R., Lameira, J., Leitão, A., & Montanari, C. A. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00204c · Cited by 137
Zanon, P. R. A., Lewald, L., & Hacker, S. M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201912075 · Cited by 116
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
Hou, N., Shuai, L., Zhang, L., Xie, X., Tang, K., Zhu, Y., Yin, Y., Zhang, W., Tan, Q., Zhong, G., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01359 · Cited by 126
Poplawski, S. E., Lai, J. H., Li, Y., Jin, Z., Liu, Y., Wu, W., Wu, Y., Zhou, Y., Sudmeier, J. L., Sanford, D. G., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400351a · Cited by 116
Recent advances in the development of covalent inhibitors
Kim, H., Hwang, Y. S., Kim, M., & Park, S. B. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00068c · Cited by 116
Development of a covalent inhibitor of gut bacterial bile salt hydrolases
Adhikari, A. A., Seegar, T. C. M., Ficarro, S. B., McCurry, M. D., Ramachandran, D., Yao, L., Chaudhari, S. N., Ndousse-Fetter, S., Banks, A. S., Marto, J. A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0467-3 · Cited by 113
A lysine–cysteine redox switch with an NOS bridge regulates enzyme function
Wensien, M., von Pappenheim, F. R., Funk, L.-M., Kloskowski, P., Curth, U., Diederichsen, U., Uranga, J., Ye, J., Fang, P., Pan, K., et al. (2021) · Nature · doi:10.1038/s41586-021-03513-3 · Cited by 116
Applications of mass spectrometry in drug metabolism: 50 years of progress
Wen, B., & Zhu, M. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.1001029 · Cited by 116
Redox-Dependent Anti-Inflammatory Signaling Actions of Unsaturated Fatty Acids
Delmastro-Greenwood, M., Freeman, B. A., & Wendell, S. G. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170341 · Cited by 114
Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach
Engel, J., Richters, A., Getlik, M., Tomassi, S., Keul, M., Termathe, M., Lategahn, J., Becker, C., Mayer‐Wrangowski, S. C., Grütter, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01082 · Cited by 123
Li, D., Li, C., Li, L., Chen, S., Wang, L., Li, Q., Wang, X., Lei, X., & Shen, Z. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2015.08.018 · Cited by 120
Rana, S., Blowers, E. C., Tebbe, C., Contreras, J. I., Radhakrishnan, P., Kizhake, S., Zhou, T., Rajule, R. N., Arnst, J. L., Munkarah, A. R., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00400 · Cited by 115
2-Sulfonylpyridines as Tunable, Cysteine-Reactive Electrophiles
Zambaldo, C., Vinogradova, E. V., Qi, X., Iaconelli, J., Suciu, R. M., Koh, M., Senkane, K., Chadwick, S. R., Sanchez, B. B., Chen, J. S., et al. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02721 · Cited by 121
“We next evaluated a core subset of these analogs (1, 5, 7-10) for in vitro reactivity with reduced glutathione (GSH) and for ARE-LUC inducing activity in reporter assays.”
MethodTargeting bacteria via iminoboronate chemistry of amine-presenting lipids
Bandyopadhyay, A., McCarthy, K. A., Kelly, M. A., & Gao, J. (2015) · Nature Communications · doi:10.1038/ncomms7561 · Cited by 113
The Design of Covalent Allosteric Drugs
Nussinov, R., & Tsai, C.-J. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124401 · Cited by 112
Shibata, Y., & Chiba, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061424 · Cited by 111
Labdane diterpenoids as potential anti-inflammatory agents
Tran, Q. T. N., Wong, W. S. F., & Chai, C. L. L. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.07.019 · Cited by 118
Dunny, E., Doherty, W., Evans, P., Malthouse, J. P. G., Nolan, D. P., & Knox, A. J. S. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400294w · Cited by 112
A Genetically Encoded aza-Michael Acceptor for Covalent Cross-Linking of Protein–Receptor Complexes
Furman, J. L., Kang, M., Choi, S., Cao, Y. J., Wold, E. D., Sun, S. B., Smider, V. V., Schultz, P. G., & Kim, C. H. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502851h · Cited by 112
Kozakov, D., Hall, D. R., Napoleon, R. L., Yueh, C., Whitty, A., & Vajda, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00586 · Cited by 115
Self-citationBlocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Scott, D. C., Hammill, J. T., Min, J., Rhee, D. Y., Connelly, M., Sviderskiy, V. O., Bhasin, D., Chen, Y., Ong, S. S., Chai, S. C., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2386 · Cited by 111
Benns, H. J., Wincott, C. J., Tate, E. W., & Child, M. A. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.06.011 · Cited by 119
Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors
Dahlin, J. L., Nelson, K. M., Strasser, J. M., Baršytė-Lovejoy, D., Szewczyk, M. M., Organ, S. L., Cuellar, M. E., Singh, G., Shrimp, J. H., Nguyen, N. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01657-3 · Cited by 113
Johnson, H. W. B., Lowe, E., Anderl, J. L., Fan, A. R., Muchamuel, T., Bowers, S., Moebius, D. C., Kirk, C. J., & McMinn, D. L. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01201 · Cited by 110
Metadata
- Authors
- Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A.
- Affiliations
- University of Washington (US)
- Boston University (US)
- Corresponding author
- Singh, Juswinder
- Venue
- Nature Reviews Drug Discovery
- Published
- 2011-04
- Volume
- 10
- Issue
- 4
- Pages
- 307-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2010993054
- Cited by
- 1,873
- References
- 71
- Citations by year
- 2026: 136 · 2025: 150 · 2024: 148 · 2023: 137 · 2022: 145 · 2021: 162 · 2020: 152 · 2019: 98 · 2018: 132 · 2017: 125 · 2016: 141 · 2015: 96 · 2014: 81 · 2013: 85 · 2012: 66
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM094551)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Click Chemistry and Applications
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- covalent inhibitors, drug safety, covalent drug design, targeted covalent inhibitors
- MeSH terms
- Animals, Pharmaceutical Preparations, Humans, Structure-Activity Relationship, Drug Design, Drug Delivery Systems, Drug Discovery, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.